Smoking-cessation therapy using varenicline: The cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence

Journal of Evaluation in Clinical Practice

Volumn 15, Issue 3, 2009, Pages 478-485

  Bolin, Kristian ^a   Mörk, Ann Christin ^b   Wilson, Koo ^c  

^a LUND UNIVERSITY   (Sweden)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Economic evaluation; Smoking cessation intervention; Sweden; Varenicline

Indexed keywords

VARENICLINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SURVIVAL; SWEDEN; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; BENZAZEPINES; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; QUINOXALINES; SMOKING; SMOKING CESSATION; SWEDEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66249086578     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2008.01045.x     Document Type: Article

References (47)

1. Wynder, E. L. Graham, E. A. (1950) Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: a study of 684 proved cases. Journal of the American Medical Association, 143, 329 396.
2. Doll, R. Hill, A. B. (1954) The mortality of doctors in relation to their smoking habits. A preliminary report. British Medical Journal, 1, 1451 1455.
3. Doll, R. Hill, A. B. (1956) Lung cancer and other causes of death in relation to smoking. A second report on the mortality of British doctors. British Medical Journal, 2, 1071 1081.
4. Hammond, E. D. Horn, D. (1958) Smoking and death rates - report on forty-four months of follow-up on 187,783 men. I. Total mortality. Journal of the American Medical Association, 166, 1159 1172.
5. Hammond, E. D. Horn, D. (1958) Smoking and death rates - report on forty-four months of follow-up on 187,783 men. II. Death rates by cause. Journal of the American Medical Association, 166, 1294 1308.
6. Thun, M. J., Apicella, L. F. Jane Henley, S. (2000) Smoking versus other risk factors as the cause of smoking-attributable deaths. Journal of the American Medical Association, 284 (6 706 712.
7. Centers for Disease Control and Prevention (CDC) (2002). Annual smoking-attributable mortality, years of potential life lost, and economic cost - United States, 1995-1999. Morbidity and Mortality Weekly Report (MMWR), 51, 300 303.
8. Callum, C. (1998) The UK Smoking Epidemic: Deaths in 1995. London : UK Health Education Authority.
9. Kaiserman, M. J. (1997) The cost of smoking in Canada, 1991. Chronic Diseases in Canada, 18, 13 19. (Pubitemid 127468559)
10. Ruff, L. K., Volmer, T., Nowak, D. Meyer, A. (2000) The economic impact of smoking in Germany. The European Respiratory Journal, 16, 385 390.
11. Bolin, K. Lindgren, B. (2007) Smoking, healthcare cost and lost productivity in Sweden, 2001. Scandinavian Journal of Public Health, 35, 187 196. (Pubitemid 46567464)
12. Hoogendoorn, M., Welsing, P. Rutten-van Mölken, M. (2008) Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Current Medical Research and Opinion, 24 (1 51 61.
13. Leistikow, B. N. (2000) The human and financial costs of smoking. Clinics in Chest Medicine, 21, 189 197. (Pubitemid 30183782)
14. Parrott, S., Godfrey, C., Raw, M., et al. (1998) Guidance for commissioners on the cost-effectiveness of smoking-cessation interventions. Thorax, 53 (Suppl 5 S1 S38.
15. Rasmussen, S. R., Prescott, E., Sørensen, T. I. A. Søgaard, J. (2005) The total lifetime health cost savings of smoking cessation to society. European Journal of Public Health, 15, 601 606. (Pubitemid 41790243)
16. Lundborg, P. (2007) Does smoking increase sick leave? Evidence using register data on Swedish workers. Tobacco Control, 16, 114 118.
17. 2 nicotinic acetylcholine receptor partial agonist, vs bupropion and placebo for smoking cessation: a randomized controlled trial. Journal of the American Medical Association, 296, 47 55.
18. 2 nicotinic acetylcholine receptor partial agonist, to bupropion and to placebo for smoking cessation. Journal of the American Medical Association, 296, 56 63.
19. Ferguson, J., Bauld, L., Chesterman, J. Judge, K. (2005) The English smoking treatment services: one-year outcomes. Addiction, 100 (Suppl 2 59 69. (Pubitemid 40525071)
20. Marlatt, A. Gordon, J. (1985) Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York : Guilford Press.
21. Hajek, P., Stead, L. F., West, R. Jarvis, M. (2005) Relapse prevention interventions for smoking cessation. Cochrane Database Systematic Review 1 CD003999.
22. Tonstad, S., Tønnesen, P., Hajek, P., Williams, K. E., Billing, C. B. Reeves, K. R. (2006) Effect of maintenance therapy with varenicline for smoking cessation. Journal of the American Medical Association, 296, 64 71.
23. Bolin, K., Mörk, A-C, Willers, S. Lindgren, B. (2008) Varenicline as compared to bupropion in smoking-cessation therapy - cost-utility results for Sweden. Respiratory Medicine, 102, 699 710.
24. Pharmaceutical Benefits Board of Sweden (2003) General Guidelines for Economic Evaluations. Stockholm : LFNAR, 21, 24, April 2003. Available at: http://www.lfn.se (last accessed 15 April 2008).
25. Meltzer, D. (1997) Accounting for future costs in medical cost-effectiveness analysis. Journal of Health Economics, 16, 33 64. (Pubitemid 27224093)
26. Lundin, D. Ramsberg, J. (2008) On survival consumption costs - a reply to Nyman. Health Economics, 17, 293 297.
27. Nyman, J. A. (2004) Should the consumption of survivors be included as a cost in cost-utility analysis? Health Economics, 13, 417 427. (Pubitemid 38660391)
28. Swedish National Board of Health and Welfare (various years) Mortality by Causes.
29. Swedish National Board of Health and Welfare (various years) Data on Inpatient Care.
30. Statistics Sweden (various years) Life Tables.
31. Statens Offentliga Utredningar (SOU) (2003) Gemensamt finansierad utjämning i kommunsektorn sou 2003 : 88, Available from http://www.regeringen.se/sb/d/108/a/1564
32. Läkemedelsstatistik, A. B. (2002) Medical Index Sweden. Stockholm : Läkemedelsstatistik AB.
33. Ghatnekar, O., Persson, U., Glader, E. L., et al. (2004) Cost of stroke in Sweden: an incidence estimate. International Journal of Technology Assessment in Health Care, 20, 375 380. (Pubitemid 39079575)
34. Fiscella, K. Franks, P. (1996) Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. Journal of the American Medical Association, 275, 1247 1251. (Pubitemid 26118498)
35. Spencer, M., Briggs, A., Grossman, R., et al. (2005) Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics, 23, 619 637. (Pubitemid 40994129)
36. Mannino, D. M., Buist, A. S., Petty, T. L., et al. (2003) Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax, 58, 388 393. (Pubitemid 36560940)
37. Trippoli, S., Vaiani, M., Lucioni, C., et al. (2001) Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics, 19, 855 863. (Pubitemid 32758549)
38. Hay, J. W. Sterling, K. L. (2005) Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics, 23, 133 141. (Pubitemid 40460653)
39. Tengs, T. Lin, T. (2003) A meta-analysis of quality of life estimates for stroke. Pharmacoeconomics, 21, 191 200. (Pubitemid 36286663)
40. Duncan, P. W., Lai, S. M. Keighley, J. (2000) Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology, 39, 835 841. (Pubitemid 30103686)
41. Statistics Sweden (1996/97) Undersökningar av Levnadsfö rhållanden.
42. Wetter, D., Cofta-Gunn, L., Fouladi, R., et al. (2004) Late relapse/sustained abstinence among former smokers: a longitudinal study. Preventive Medicine, 39, 1156 1163. (Pubitemid 39468630)
43. Krall, E., Garvey, A. Garcia, R. (2002) Smoking relapse after 2 years of abstinence: findings from the VA normative aging study. Nicotine and Tobacco Research, 4, 95 100. (Pubitemid 34521101)
44. Ekman, M. (2002) Studies in health economics - modelling and data analysis of costs and survival. Diss., Stockholm School of Economics, Stockholm.
45. Kenkel, D. (2006) WTP- and QALY-based approaches to valuing health for policy: common ground and disputed territory. Environmental & Resource Economics, 34, 419 437.
46. King, J. T., Tsevat, J., Lave, J. R., et al. (2005) Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Medical Decision Making, 25, 667 677. (Pubitemid 41667135)
47. Bolin, K., Lindgren, B. Willers, S. (2006) The cost utility of bupropion in smoking cessation health programs simulation model results for Sweden Chest, 129, 651 660.